Drugs / VTX3232
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06771115 | Jan → Sep 2025 | obesity disorder | Zomagen Biosciences Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06556173 | Aug 2024 → Apr 2025 | Parkinson disease | Zomagen Biosciences Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VTX3232 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06556173 ↗ |